Therapy Adjuncts

Genta And NCI Expand Joint Clinical Trials Program With Genasense

Published in Gene Therapy Weekly, December 20th, 2001

Genta, Inc., (GNTA) has expanded its relationship with the U.S. National Cancer Institute (NCI) for new clinical trials involving its lead antisense compound, Genasense.

Pursuant to an existing Cooperative Research and Development Agreement (CRADA), the NCI has solicited new proposals from investigators to study Genasense in combination with standard anticancer therapy. Specific trials were requested in a broad group of diseases, including cancer of the prostate, breast, lung, colon, bladder, ovary, uterus, kidney and pancreas, and in Merkel cell tumor and non-Hodgkin lymphoma. Under the CRADA terms, NCI and Genta will jointly review and approve the initiation of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-12-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry